Qube Research & Technologies (QRT)’s Esperion Therapeutics ESPR Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-208,161	Closed	-$570K	–	3641
2026 Q1	$570K	Buy	+208,161	New	+$659K	﹤0.01%	2693
2025 Q3	–	Sell	-485,603	Closed	-$478K	–	3686
2025 Q2	$478K	Buy	485,603 +342,067	+238%	+$343K	﹤0.01%	2709
2025 Q1	$207K	Sell	143,536 -85,194	-37%	-$157K	﹤0.01%	2855
2024 Q4	$503K	Sell	228,730 -522,054	-70%	-$1.22M	﹤0.01%	2474
2024 Q3	$1.24M	Sell	750,784 -351,864	-32%	-$710K	﹤0.01%	1951
2024 Q2	$2.45M	Sell	1,102,648 -504,664	-31%	-$1.19M	﹤0.01%	1536
2024 Q1	$4.31M	Buy	1,607,312 +1,172,071	+269%	+$2.85M	0.01%	1322
2023 Q4	$1.3M	Buy	435,241 +403,679	+1,279%	+$524K	﹤0.01%	1771
2023 Q3	$30.9K	Sell	31,562 -92,419	-75%	-$134K	﹤0.01%	3009
2023 Q2	$172K	Buy	123,981 +78,848	+175%	+$110K	﹤0.01%	1819
2023 Q1	$71.8K	Buy	+45,133	New	+$233K	﹤0.01%	2180

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ESPR Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 208,161 shares — an estimated $570K sold.

Qube Research & Technologies (QRT) first reported a position in ESPR in Q1 2023 and held it in 11 quarters. The position peaked at $4.31M in Q1 2024. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Qube Research & Technologies (QRT) reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 208,161 Esperion Therapeutics shares in Q2 2026, an estimated $570K.
Qube Research & Technologies (QRT) first reported a position in Esperion Therapeutics in Q1 2023 and held it in 11 quarters.
Qube Research & Technologies (QRT)'s Esperion Therapeutics position peaked at $4.31M in Q1 2024.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.